Caponetti Angelo Giuseppe, Accietto Antonella, Saturi Giulia, Ponziani Alberto, Sguazzotti Maurizio, Massa Paolo, Giovannetti Alessandro, Ditaranto Raffaello, Parisi Vanda, Leone Ornella, Guaraldi Pietro, Cortelli Pietro, Gagliardi Christian, Longhi Simone, Galiè Nazzareno, Biagini Elena
Cardiology Unit, Cardiac Thoracic and Vascular Department, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
Front Cardiovasc Med. 2023 Mar 9;10:1146725. doi: 10.3389/fcvm.2023.1146725. eCollection 2023.
Cardiac amyloidosis is a serious and progressive infiltrative disease caused by the deposition of amyloid fibrils in the heart. In the last years, a significant increase in the diagnosis rate has been observed owing to a greater awareness of its broad clinical presentation. Cardiac amyloidosis is frequently associated to specific clinical and instrumental features, so called "red flags", and it appears to occur more commonly in particular clinical settings such as multidistrict orthopedic conditions, aortic valve stenosis, heart failure with preserved or mildly reduced ejection fraction, arrhythmias, plasma cell disorders. Multimodality approach and new developed techniques such PET fluorine tracers or artificial intelligence may contribute to strike up extensive screening programs for an early recognition of the disease.
心脏淀粉样变性是一种由淀粉样原纤维沉积于心脏所引起的严重的进行性浸润性疾病。近年来，由于对其广泛临床表现的认识提高，诊断率显著上升。心脏淀粉样变性常与特定的临床和影像学特征（即所谓的“红旗征”）相关，并且似乎更常见于特定的临床情况，如多部位骨科疾病、主动脉瓣狭窄、射血分数保留或轻度降低的心力衰竭、心律失常、浆细胞疾病。多模态方法以及新开发的技术，如PET氟示踪剂或人工智能，可能有助于启动广泛的筛查计划，以便早期识别该疾病。
